Cresco Labs (CRLBF) Cash from Financing Activities (2019 - 2025)
Cresco Labs' (CRLBF) quarterly Cash from Financing Activities came in at -$1.8 million in Q4 2025, up 95.73% YoY from -$916037.2 in Q4 2024, and up 97.48% on a QoQ basis from -$71.1 million in Q3 2025.
Cresco Labs (CRLBF) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Cash from Financing Activities data on file, last reported at -$1.8 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 95.73% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$117.4 million (down 207.07% YoY) and the FY2025 annual result came in at -$82.1 million, down 14.84% from the prior year.
- Cash from Financing Activities advanced to -$1.8 million in Q4 2025, from -$71.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $132.2 million in Q1 2021 to a low of -$71.1 million in Q3 2025.
- A 5-year average of $371486.6 and a median of -$3.1 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 860.8% — and 2025, when it sank 2785.39%.
- Tracing CRLBF's Cash from Financing Activities over 5 years: stood at -$2.4 million in 2021, then rose by 14.48% to -$2.0 million in 2022, then slumped by 86.21% to -$3.8 million in 2023, then sank by 1011.42% to -$42.0 million in 2024, then soared by 95.73% to -$1.8 million in 2025.
- The last three Cash from Financing Activities figures came in at -$1.8 million (Q4 2025), -$71.1 million (Q3 2025), and -$42.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Cresco Labs | 304.06 Mn | 239.95 Mn | 86.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.79 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | -71.10 Mn |
| Sep 30, 2025 | -71.10 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Dec 31, 2022 | -2.03 Mn |
| Dec 31, 2022 | -2.03 Mn |
| Sep 30, 2022 | -9.11 Mn |
| Sep 30, 2022 | -9.11 Mn |
| Jun 30, 2022 | -69.14 Mn |
| Jun 30, 2022 | -69.14 Mn |
| Mar 31, 2022 | -6.37 Mn |
| Mar 31, 2022 | -6.37 Mn |